Ahammune Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.35 M
as on 17-07-2024
- Paid Up Capital ₹ 0.19 M
as on 17-07-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 27.29%
(FY 2023)
- Profit 62.78%
(FY 2023)
- Ebitda 51.15%
(FY 2023)
- Net Worth -4.68%
(FY 2023)
- Total Assets -6.00%
(FY 2023)
About Ahammune Biosciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.35 M and a paid-up capital of Rs 0.19 M, as per Ministry of Corporate Affairs (MCA) records.
Uday Chatterjee, Tanjore Soundararajan, Naganand Doraswamy, and Three other members serve as directors at the Company.
- CIN/LLPIN
U74999PN2016PTC164337
- Company No.
164337
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 May 2016
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ahammune Biosciences?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Uday Chatterjee  | Director | 20-Feb-2021 | Current |
| Parul Ganju | Director | 05-May-2016 | Current |
| Tanjore Soundararajan | Director | 08-May-2021 | Current |
Naganand Doraswamy  | Director | 20-Feb-2021 | Current |
| Satyajit Rath | Director | 10-Oct-2017 | Current |
| Krishnamurthy Natarajan | Director | 05-May-2016 | Current |
Financial Performance and Corporate Structure Insights of Ahammune Biosciences.
Ahammune Biosciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 27.29% increase. The company also saw a substantial improvement in profitability, with a 62.78% increase in profit. The company's net worth dipped by a decrease of 4.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ahammune Biosciences?
In 2023, Ahammune Biosciences had a promoter holding of 74.60% and a public holding of 25.40%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ahammune Biosciences?
Unlock and access historical data on people associated with Ahammune Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ahammune Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ahammune Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
